Clinical Spectrum of Primary Hyperoxaluria Type 1: Experience of a Tertiary Center

Overview

Journal Nephrol Ther

Publisher John Libbey Eurotext

Specialty Nephrology

Date 2017 Feb 6

PMID 28161266

Citations 24

Authors

Neveen A Soliman

Marwa M Nabhan

Safaa M Abdelrahman

Hanan Abdelaziz

Rasha Helmy

Khaled Ghanim

Hafez M Bazaraa

Ahmed M Badr

Omar A Tolba

Magd A Kotb

Khaled M Eweeda

Alaa Fayez

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Primary hyperoxalurias are rare inborn errors of metabolism resulting in increased endogenous production of oxalate that leads to excessive urinary oxalate excretion. Diagnosis of primary hyperoxaluria type 1 (PH1) is a challenging issue and depends on diverse diagnostic tools including biochemical analysis of urine, stone analysis, renal biopsy, genetic studies and in some cases liver biopsy for enzyme assay. We characterized the clinical presentation as well as renal and extrarenal phenotypes in PH1 patients.

Methods: This descriptive cohort study included patients with presumable PH1 presenting with nephrolithiasis and/or nephrocalcinosis (NC). Precise clinical characterization of renal phenotype as well as systemic involvement is reported. AGXT mutational analysis was performed to confirm the diagnosis of PH1.

Results: The study cohort included 26 patients with presumable PH1 with male to female ratio of 1.4:1. The median age at time of diagnosis was 6 years, nevertheless the median age at initial symptoms was 3 years. Thirteen patients (50%) were diagnosed before the age of 5 years. Two patients had no symptoms and were diagnosed while screening siblings of index patients. Seventeen patients (65.4%) had reached end-stage renal disease (ESRD): 6/17 (35.3%) during infancy, 4/17 (23.5%) in early childhood and 7/17 (41.29%) in late childhood. Two patients (7.7%) had clinically manifest extra renal (retina, heart, bone, soft tissue) involvement. Mutational analysis of AGXT gene confirmed the diagnosis of PH1 in 15 out of 19 patients (79%) where analysis had been performed. Fifty percent of patients with maintained renal functions had projected 10 years renal survival.

Conclusion: PH1 is a heterogeneous disease with wide spectrum of clinical, imaging and functional presentation. More than two-thirds of patients presented prior to the age of 5 years; half of them with the stormy course of infantile PH1. ESRD was the commonest presenting manifestation in two-thirds of our cohort.

Citing Articles

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.

Frishberg Y, Hayes W, Shasha-Lavsky H, Sas D, Michael M, Sellier-Leclerc A Front Pediatr. 2024; 12:1392644.

PMID: 39355649 PMC: 11443422. DOI: 10.3389/fped.2024.1392644.

Bone health in children with primary hyperoxaluria type 1 following liver and kidney transplantation.

Buscher R, Pape L, Buscher A Front Pediatr. 2024; 12:1353880.

PMID: 38455394 PMC: 10917879. DOI: 10.3389/fped.2024.1353880.

Boussetta A, Fatnassi R, Jellouli M, Maamouri R, Mrad R, Gargah T Tunis Med. 2024; 101(7):626-630.

PMID: 38445424 PMC: 11217970.

Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1.

Torella L, Klermund J, Bilbao-Arribas M, Tamayo I, Andrieux G, Chmielewski K EMBO Mol Med. 2024; 16(1):112-131.

PMID: 38182795 PMC: 10897483. DOI: 10.1038/s44321-023-00008-8.

Nedosiran: First Approval.

Syed Y Drugs. 2023; 83(18):1729-1733.

PMID: 38060091 PMC: 10803381. DOI: 10.1007/s40265-023-01976-4.

References

van der Hoeven S, van Woerden C, Groothoff J . Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012; 27(10):3855-62. DOI: 10.1093/ndt/gfs320. View

Hoppe B, Latta K, von Schnakenburg C, Kemper M . Primary hyperoxaluria--the German experience. Am J Nephrol. 2005; 25(3):276-81. DOI: 10.1159/000086358. View

Broyer M, Brunner F, Brynger H, Dykes S, Ehrich J, Fassbinder W . Kidney transplantation in primary oxalosis: data from the EDTA Registry. Nephrol Dial Transplant. 1990; 5(5):332-6. DOI: 10.1093/ndt/5.5.332. View

van Woerden C, Groothoff J, Wanders R, Davin J, Wijburg F . Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant. 2003; 18(2):273-9. DOI: 10.1093/ndt/18.2.273. View

Hattori S, Yosioka K, Honda M, Ito H . The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. Pediatr Nephrol. 2002; 17(6):456-61. DOI: 10.1007/s00467-002-0848-8. View

Harambat J, van Stralen K, Espinosa L, Groothoff J, Hulton S, Cerkauskiene R . Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol. 2012; 7(3):458-65. PMC: 3302673. DOI: 10.2215/CJN.07430711. View

Belostotsky R, Seboun E, Idelson G, Milliner D, Becker-Cohen R, Rinat C . Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010; 87(3):392-9. PMC: 2933339. DOI: 10.1016/j.ajhg.2010.07.023. View

Jamieson N . A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984-2004. Am J Nephrol. 2005; 25(3):282-9. DOI: 10.1159/000086359. View

Daudon M, Jungers P . Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 2004; 98(2):p31-6. DOI: 10.1159/000080261. View

10.

Cramer S, Ferree P, Lin K, Milliner D, Holmes R . The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet. 1999; 8(11):2063-9. DOI: 10.1093/hmg/8.11.2063. View

11.

Purdue P, Lumb M, Fox M, Griffo G, Povey S, Danpure C . Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics. 1991; 10(1):34-42. DOI: 10.1016/0888-7543(91)90481-s. View

12.

Danpure C, Jennings P . Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 1986; 201(1):20-4. DOI: 10.1016/0014-5793(86)80563-4. View

13.

Gargah T, Khelil N, Gharbi Y, Karoui W, Trabelsi M, Rajhi H . Primary hyperoxaluria type 1 in Tunisian children. Tunis Med. 2011; 89(2):163-7. View

14.

Lewis M, Shaw J, Reid C, Evans J, Webb N, Verrier-Jones K . Demography and management of childhood established renal failure in the UK (chapter 13). Nephrol Dial Transplant. 2007; 22 Suppl 7:vii165-75. DOI: 10.1093/ndt/gfm336. View

15.

Milliner D, Eickholt J, Bergstralh E, Wilson D, Smith L . Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med. 1994; 331(23):1553-8. DOI: 10.1056/NEJM199412083312304. View

16.

Cochat P, Hulton S, Acquaviva C, Danpure C, Daudon M, Marchi M . Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012; 27(5):1729-36. DOI: 10.1093/ndt/gfs078. View

17.

Cochat P, Rumsby G . Primary hyperoxaluria. N Engl J Med. 2013; 369(7):649-58. DOI: 10.1056/NEJMra1301564. View

18.

Cochat P, Koch Nogueira P, Mahmoud M, Jamieson N, Scheinman J, Rolland M . Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr. 1999; 135(6):746-50. DOI: 10.1016/s0022-3476(99)70095-8. View

19.

Milliner D . The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol. 2005; 25(2):154-60. DOI: 10.1159/000085407. View

20.

Cochat P, Groothoff J . Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol. 2013; 28(12):2273-81. DOI: 10.1007/s00467-013-2444-5. View